Organon & Co. (NYSE:OGN) Shares Gap Up – Still a Buy?

Organon & Co. (NYSE:OGN) gapped up prior to trading on Thursday . The stock had previously closed at $14.70, but opened at $15.74. Organon & Co. shares last traded at $16.45, with a volume of 1,169,714 shares traded.

Analyst Ratings Changes

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $21.33.

Organon & Co. Stock Up 12.4 %

The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The firm has a market capitalization of $4.26 billion, a P/E ratio of 3.29, a PEG ratio of 0.83 and a beta of 0.76. The firm’s fifty day moving average price is $15.33 and its 200-day moving average price is $17.54.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. As a group, equities research analysts forecast that Organon & Co. will post 3.82 earnings per share for the current year.

Institutional Trading of Organon & Co.

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Organon & Co. by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company’s stock worth $453,593,000 after buying an additional 218,165 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after acquiring an additional 11,140,388 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Organon & Co. by 1.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company’s stock valued at $147,634,000 after purchasing an additional 136,760 shares during the last quarter. Geode Capital Management LLC grew its stake in Organon & Co. by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 4,260,218 shares of the company’s stock valued at $63,582,000 after purchasing an additional 12,110 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Organon & Co. by 0.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,333,703 shares of the company’s stock worth $49,739,000 after purchasing an additional 10,652 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.